SLC5A2 and type 2 diabetes mellitus: Currently, sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are one of the main treatments for reducing high cardiovascular (CV) mortality in patients with type 2 diabetes (T2D) [1].